Non-Hodgkin's Lymphoma

Showing 1 - 25 of 294

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2023

DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Louisville, Kentucky
  • +6 more
Nov 14, 2022

Living Conditions After Non-Hodgkin's Lymphoma in France

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Data collection
  • Questionnaires
  • Dijon, France
    Chu Dijon Bourgogne
Oct 13, 2022

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Bethesda, Minneapolis (biological, drug,

Recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
  • +1 more
Aug 20, 2022

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 18, 2022

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
  • Mycosis Fungoides
  • Non-Hodgkin's Lymphoma
    • Duarte, California
    • +12 more
    Jun 17, 2022

    Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma Trial (cerdulatinib)

    Available
    • Relapsed/Refractory Chronic Lymphocytic Leukemia
    • Non-hodgkin's Lymphoma
    • (no location specified)
    May 6, 2022

    Non-Hodgkin's Lymphoma Trial in Hangzhou (ThisCART19A)

    Recruiting
    • Non-Hodgkin's Lymphoma
    • ThisCART19A
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Apr 21, 2022

    Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia Trial in Vancouver, Ottawa (CLIC-1901)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • CLIC-1901
    • Vancouver, British Columbia, Canada
    • +1 more
    Mar 26, 2022

    Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Atlanta (Fludarabine, Melphalan,

    Completed
    • Chronic Myelogenous Leukemia
    • +9 more
    • Atlanta, Georgia
      Northside Hospital
    Apr 4, 2022

    Non-Hodgkin's Lymphoma Trial in Vitoria-Gasteiz (RiTUXimab Injection [Truxima])

    Recruiting
    • Non-Hodgkin's Lymphoma
    • RiTUXimab Injection [Truxima]
    • Vitoria-Gasteiz, Alava, Spain
      Hospital Universitario Araba- Sede Txagorritxu
    Mar 30, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma Trial in United States (CG-806)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Phoenix, Arizona
    • +30 more
    Mar 28, 2022

    Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Trial in Oklahoma City, Houston (Fenretinide,

    Terminated
    • Acute Myelogenous Leukemia
    • +2 more
    • Oklahoma City, Oklahoma
    • +1 more
    Mar 17, 2022

    Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML) Trial (Venetoclax)

    Available
    • Chronic Lymphocytic Leukemia (CLL)
    • +6 more
    • (no location specified)
    Mar 28, 2022

    Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

    Active, not recruiting
    • Non-Hodgkin's Lymphoma
    • Hodgkin's Lymphoma
    • CAR.CD30 T cells
    • Chapel Hill, North Carolina
    • +2 more
    Mar 16, 2022

    Non-hodgkin's Lymphoma Trial in Beijing (Chiauranib, Chidamide)

    Completed
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Mar 7, 2022

    Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia Trial in Atlanta, Saint Louis, Columbus

    Active, not recruiting
    • Acute Myelogenous Leukemia
    • +10 more
    • Atlanta, Georgia
    • +2 more
    Feb 9, 2022

    Non-Hodgkin's Lymphoma Trial in China (single dose of CNCT19)

    Recruiting
    • Non-Hodgkin's Lymphoma
    • single dose of CNCT19
    • Fuzhou, Fujian, China
    • +17 more
    Feb 17, 2022

    Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

    Recruiting
    • Non-Hodgkin's Lymphoma
    • +2 more
    • CD19.CAR-CD28Z T Cells - dose escalation 2
    • CD19.CAR-CD28Z T Cells - dose escalation 1
    • Houston, Texas
    • +1 more
    Feb 10, 2022

    Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

    Active, not recruiting
    • Hodgkin's Lymphoma
    • Non-Hodgkin's Lymphoma
    • autologous CAR.CD30 EBV specific-CTLs
    • Houston, Texas
    • +1 more
    Feb 4, 2022

    Non-hodgkin's Lymphoma Trial in Langfang (CD19+22 CAR-T cells)

    Recruiting
    • Non-hodgkin's Lymphoma
    • CD19+22 CAR-T cells
    • Langfang, Hebei, China
      Hebei Yanda Ludaopei Hospital
    Jan 11, 2022

    Leukemia, Multiple Myeloma, Myelodysplastic Syndrome Trial in New York (biological, procedure, radiation, drug)

    Active, not recruiting
    • Leukemia
    • +3 more
    • Palifermin
    • +6 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jan 21, 2022

    Multiple Myeloma, Non-Hodgkin's Lymphoma Trial in United States (Romidepsin, Lenalidomide)

    Active, not recruiting
    • Multiple Myeloma
    • Non-Hodgkin's Lymphoma
    • Hartford, Connecticut
    • +6 more
    Jan 3, 2022

    Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma Trial in Australia, Germany, United States

    Terminated
    • Acute Myeloid Leukemia
    • +2 more
    • Duarte, California
    • +16 more
    Dec 3, 2021

    Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia Trial in Winston-Salem

    Recruiting
    • Acute Myelogenous Leukemia
    • +9 more
      • Winston-Salem, North Carolina
        Wake Forest Baptist Health
      Nov 23, 2021